文献速递慢性肾脏病遗传性与小管间质肾病

普伐他汀对早期常染色体显性多囊肾病成人患者肾脏结局的随机对照试验

A randomized controlled trial evaluated the effect of pravastatin on kidney disease outcomes in adult patients with early-stage autosomal dominant polycystic kidney disease.
PubMed 文献 · Kidney Int · 2025-10-10

本研究为前瞻性随机双盲安慰剂对照试验,纳入150例eGFR≥60 ml/min/1.73 m2的早期ADPKD成人患者,随机接受普伐他汀40 mg或安慰剂治疗两年。主要结局为身高调整总肾脏体积的年变化率,结果显示普伐他汀组与安慰剂组无显著差异,且肾脏血流量和mGFR的年变化率亦无显著差异。

要点

  • 普伐他汀未显著减缓早期ADPKD患者HtTKV的年增长速率。
  • 普伐他汀对肾脏血流量和mGFR的下降无显著影响。
  • 在快速进展亚组(Mayo影像分类1C、D、E)中亦呈相似趋势。

核心结论

  • 在肾功能保留的ADPKD成人患者中,普伐他汀未能减缓HtTKV增加,对肾脏血流量和肾功能下降也无影响。

研究设计与样本

  • 前瞻性、随机、对照、双盲临床试验,纳入150例(52男98女,25-60岁)ADPKD患者,eGFR≥60 ml/min/1.73 m2。
  • 患者随机接受普伐他汀40 mg或安慰剂治疗两年。

主要发现

  • HtTKV年增长率中位数(四分位距):安慰剂组3.1%(1.4, 6.8),普伐他汀组4.3%(3.0, 6.6)。
  • 肾脏血流量年下降率(ml/min/1.73 m2):安慰剂组-32.7(-62.1, -0.8),普伐他汀组-15.1(-50.7, 14.4)。
  • mGFR年变化中位数(ml/min/1.73 m2):安慰剂组-2.3(-5.1, 1.6),普伐他汀组-1.4(-6.4, 2.0)。
  • 总体而言,两组间任何参数均无显著差异。
  • 在疾病进展较快(Mayo影像分类1C、D、E)的患者中趋势相似。

临床怎么用

  • 对于早期ADPKD且肾功能保留的成人患者,不推荐使用普伐他汀以延缓肾脏体积增长或肾功能下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Whether treatment with pravastatin mitigates kidney dysfunction in adult patients with early autosomal dominant polycystic kidney disease (ADPKD) is unknown. To answer this, we performed a prospective, randomized, controlled, double-blind clinical trial in 150 patients (52 males and 98 females; 25-60 years) with ADPKD, and an estimated glomerular filtration rate (eGFR) of 60 ml/min or more per 1.73 m2. METHODS: Patients were randomly assigned to receive 40 mg of pravastatin or a placebo for two years. The primary outcome was the annual change in height-adjusted total kidney volume (HtTKV). Secondary outcomes were the annual change in kidney blood flow by magnetic resonance angiography and the annual change in measured GFR (mGFR). RESULTS: Among the participants who underwent randomization, the annual rate of increase in HtTKV median (interquartile range) was 3.1% (1.4, 6.8) in the placebo and the pravastatin 4.3% (3.0, 6.6) group. The annual rate of decline in kidney blood flow (ml/min per 1.73 m2) was -32.7 (-62.1, -0.8) in placebo vs. -15.1 (-50.7, 14.4) in the pravastatin group. The median change in mGFR (ml/min per 1.73 m2) -2.3 (-5.1, 1.6) for placebo and -1.4 (-6.4, 2.0) for the pravastatin group. Overall, no parameter differed significantly between treatment groups. There was a similar trend in patients with faster disease progression (Mayo Imaging Class 1C, D, and E). CONCLUSIONS: Among adult patients with ADPKD and preserved kidney function, pravastatin did not slow the increase in HtTKV and had no effect on slowing the decline in kidney blood flow and kidney function compared to placebo. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT03273413.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Gitomer BY, Ostrow A, Wang W, et al. A randomized controlled trial evaluated the effect of pravastatin on kidney disease outcomes in adult patients with early-stage autosomal dominant polycystic kidney disease. Kidney Int. 2025. PMID: 41077128. doi:10.1016/j.kint.2025.08.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。